Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Discovery of 4-oxoquinolines, a new chemical class of anti-HIV-1 compounds.

Shiroishi-Wakatsuki T, Maejima-Kitagawa M, Hamano A, Murata D, Sukegawa S, Matsuoka K, Ode H, Hachiya A, Imahashi M, Yokomaku Y, Nomura N, Sugiura W, Iwatani Y.

Antiviral Res. 2019 Feb;162:101-109. doi: 10.1016/j.antiviral.2018.12.012. Epub 2018 Dec 21.

2.

Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.

Nemoto M, Hattori H, Maeda N, Akita N, Muramatsu H, Moritani S, Kawasaki T, Maejima M, Ode H, Hachiya A, Sugiura W, Yokomaku Y, Horibe K, Iwatani Y.

Sci Rep. 2018 May 3;8(1):6956. doi: 10.1038/s41598-018-25260-8.

3.

Performance Evaluation of a Genotypic Tropism Test Using HIV-1 CRF01_AE Isolates in Japan.

Matsuda M, Louvel S, Sugiura W, Haas A, Pfeifer N, Yokomaku Y, Iwatani Y, Kaiser R, Klimkait T.

Jpn J Infect Dis. 2018 Jul 24;71(4):264-266. doi: 10.7883/yoken.JJID.2017.482. Epub 2018 Apr 27.

4.

Distribution of Human Papillomavirus Genotype in Anal Condyloma Acuminatum Among Japanese Men: The Higher Prevalence of High Risk Human Papillomavirus in Men Who Have Sex with Men with HIV Infection.

Furukawa S, Uota S, Yamana T, Sahara R, Iihara K, Yokomaku Y, Iwatani Y, Sugiura W.

AIDS Res Hum Retroviruses. 2018 Apr;34(4):375-381. doi: 10.1089/AID.2017.0197. Epub 2018 Mar 13.

PMID:
29183133
5.

Dynamic HIV-1 genetic recombination and genotypic drug resistance among treatment-experienced adults in northern Ghana.

Nii-Trebi NI, Brandful JAM, Ibe S, Sugiura W, Barnor JS, Bampoh PO, Yamaoka S, Matano T, Yoshimura K, Ishikawa K, Ampofo WK.

J Med Microbiol. 2017 Nov;66(11):1663-1672. doi: 10.1099/jmm.0.000621. Epub 2017 Oct 25.

PMID:
29068286
6.

Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Madero JS, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Alberto Arnaiz J, Cooper D, Rockstroh JK, Mallon P, Emery S; MARCH study group.

HIV Med. 2018 Jan;19(1):65-71. doi: 10.1111/hiv.12532. Epub 2017 Jul 13.

PMID:
28703491
7.

Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naïve chronic hepatitis B patients.

Koike K, Suyama K, Ito H, Itoh H, Sugiura W.

Hepatol Res. 2018 Jan;48(1):59-68. doi: 10.1111/hepr.12902. Epub 2017 May 24.

PMID:
28374496
8.

[Investigation of the Pathophysiology and Diagnostic Methods Through a Case of Acute HIV Infection in which the Western Blot Method Remained Negative Over the Long Term and the 4th Generation Screening Assay Became Negative for a Certain Period of Time after Initiating Antiretroviral Therapy].

Niwa K, Yamamoto Y, Yotsumoto M, Chikasawa Y, Bingo M, Muramatsu T, Seita I, Otaki M, Ogata K, Hagiwara T, Suzuki T, Amano K, Kimura M, Yoneyama A, Takaya S, Koibuchi T, Kato S, Okazaki R, Hachiya A, Sugiura W, Fukutake K.

Kansenshogaku Zasshi. 2017 Jan;91(1):7-12. Japanese.

PMID:
30277681
9.

A Case Study of Rat Bite Fever Caused by Streptobacillus moniliformis.

Hayakawa Y, Suzuki J, Suzuki M, Sugiura W, Ohkusu K.

Jpn J Infect Dis. 2017 May 24;70(3):323-325. doi: 10.7883/yoken.JJID.2016.270. Epub 2016 Dec 22.

10.

Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs.

Kumada H, Koike K, Suyama K, Ito H, Itoh H, Sugiura W.

Hepatol Res. 2017 Sep;47(10):1032-1041. doi: 10.1111/hepr.12842. Epub 2016 Dec 21.

PMID:
27862721
11.

Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome.

Ikuma M, Watanabe D, Yagura H, Ashida M, Takahashi M, Shibata M, Asaoka T, Yoshino M, Uehira T, Sugiura W, Shirasaka T.

Intern Med. 2016;55(20):3059-3063. Epub 2016 Oct 15.

12.

The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum.

Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S; Japanese HIV-MDR Study Group.

Jpn J Infect Dis. 2017 Mar 24;70(2):158-160. doi: 10.7883/yoken.JJID.2015.599. Epub 2016 Jun 30.

13.

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.

Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, Gatanaga H.

J Antimicrob Chemother. 2016 Oct;71(10):2760-6. doi: 10.1093/jac/dkw224. Epub 2016 Jun 20.

PMID:
27330069
14.

Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.

Pett SL, Amin J, Horban A, Andrade-Villanueva J, Losso M, Porteiro N, Sierra Madero J, Belloso W, Tu E, Silk D, Kelleher A, Harrigan R, Clark A, Sugiura W, Wolff M, Gill J, Gatell J, Fisher M, Clarke A, Ruxrungtham K, Prazuck T, Kaiser R, Woolley I, Arnaiz JA, Cooper D, Rockstroh JK, Mallon P, Emery S; Maraviroc Switch (MARCH) Study Group.

Clin Infect Dis. 2016 Jul 1;63(1):122-32. doi: 10.1093/cid/ciw207. Epub 2016 Apr 5.

15.

Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance.

Nakashima M, Ode H, Suzuki K, Fujino M, Maejima M, Kimura Y, Masaoka T, Hattori J, Matsuda M, Hachiya A, Yokomaku Y, Suzuki A, Watanabe N, Sugiura W, Iwatani Y.

Front Microbiol. 2016 Feb 3;7:61. doi: 10.3389/fmicb.2016.00061. eCollection 2016.

16.

Molecular epidemiology of enteric viruses in patients with acute gastroenteritis in Aichi prefecture, Japan, 2008/09-2013/14.

Nakamura N, Kobayashi S, Minagawa H, Matsushita T, Sugiura W, Iwatani Y.

J Med Virol. 2016 Jul;88(7):1180-6. doi: 10.1002/jmv.24445. Epub 2015 Dec 22.

PMID:
26647761
17.

Quasispecies Analyses of the HIV-1 Near-full-length Genome With Illumina MiSeq.

Ode H, Matsuda M, Matsuoka K, Hachiya A, Hattori J, Kito Y, Yokomaku Y, Iwatani Y, Sugiura W.

Front Microbiol. 2015 Nov 12;6:1258. doi: 10.3389/fmicb.2015.01258. eCollection 2015.

18.

A cell-free enzymatic activity assay for the evaluation of HIV-1 drug resistance to protease inhibitors.

Matsunaga S, Masaoka T, Sawasaki T, Morishita R, Iwatani Y, Tatsumi M, Endo Y, Yamamoto N, Sugiura W, Ryo A.

Front Microbiol. 2015 Oct 31;6:1220. doi: 10.3389/fmicb.2015.01220. eCollection 2015.

19.

HIV-1 CRF01_AE and Subtype B Transmission Networks Crossover: A New AE/B Recombinant Identified in Japan.

Hosaka M, Fujisaki S, Masakane A, Hattori J, Shiino T, Gatanaga H, Shigemi U, Okazaki R, Hachiya A, Matsuda M, Ibe S, Iwatani Y, Yokomaku Y, Sugiura W; Japanese Drug Resistance HIV-1 Surveillance Network Team.

AIDS Res Hum Retroviruses. 2016 May;32(5):412-9. doi: 10.1089/aid.2015.0192. Epub 2015 Nov 16.

20.

Structural Insights into HIV-1 Vif-APOBEC3F Interaction.

Nakashima M, Ode H, Kawamura T, Kitamura S, Naganawa Y, Awazu H, Tsuzuki S, Matsuoka K, Nemoto M, Hachiya A, Sugiura W, Yokomaku Y, Watanabe N, Iwatani Y.

J Virol. 2015 Nov 4;90(2):1034-47. doi: 10.1128/JVI.02369-15. Print 2016 Jan 15.

21.

A Novel Drug-Resistant HIV-1 Circulating Recombinant Form CRF76_01B Identified by Near Full-Length Genome Analysis.

Ogawa S, Hachiya A, Hosaka M, Matsuda M, Ode H, Shigemi U, Okazaki R, Sadamasu K, Nagashima M, Toyokawa T, Tateyama M, Tanaka Y, Sugiura W, Yokomaku Y, Iwatani Y.

AIDS Res Hum Retroviruses. 2016 Mar;32(3):284-9. doi: 10.1089/AID.2015.0304. Epub 2015 Dec 1.

PMID:
26528581
22.

Virological characteristics of hepatitis B genotype G/A2 recombination virus in Japan.

Tsuzuki Y, Watanabe T, Iio E, Fujisaki S, Ibe S, Kani S, Hamada-Tsutsumi S, Yokomaku Y, Iwatani Y, Sugiura W, Okuse C, Okumura A, Sato Y, Tanaka Y.

Hepatol Res. 2016 Jul;46(8):775-83. doi: 10.1111/hepr.12612. Epub 2015 Nov 19.

PMID:
26517979
23.

Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan.

Hattori J, Shiino T, Gatanaga H, Mori H, Minami R, Uchida K, Sadamasu K, Kondo M, Sugiura W; Japanese Drug Resistance HIV-1 Surveillance Network.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):367-73. doi: 10.1097/QAI.0000000000000861.

PMID:
26428230
24.

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.

Nishizawa M, Matsuda M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, Sugiura W.

PLoS One. 2015 Sep 11;10(9):e0135941. doi: 10.1371/journal.pone.0135941. eCollection 2015.

25.

An Hepatitis C Virus (HCV)/HIV Co-Infected Patient who Developed Severe Hepatitis during Chronic HCV Infection: Sustained Viral Response with Simeprevir Plus Peginterferon-Alpha and Ribavirin.

Hirashima N, Iwase H, Shimada M, Imamura J, Sugiura W, Yokomaku Y, Watanabe T.

Intern Med. 2015;54(17):2173-7. doi: 10.2169/internalmedicine.54.4344. Epub 2015 Sep 1.

26.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun. No abstract available.

27.

Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.

Hachiya A, Ode H, Matsuda M, Kito Y, Shigemi U, Matsuoka K, Imamura J, Yokomaku Y, Iwatani Y, Sugiura W.

Antiviral Res. 2015 Jul;119:84-8. doi: 10.1016/j.antiviral.2015.04.014. Epub 2015 May 5.

PMID:
25956162
28.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

29.

Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.

Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, Koike K.

PLoS One. 2015 Mar 6;10(3):e0119145. doi: 10.1371/journal.pone.0119145. eCollection 2015.

30.

APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese.

Sakurai D, Iwatani Y, Ohtani H, Naruse TK, Terunuma H, Sugiura W, Kimura A.

Immunogenetics. 2015 Apr;67(4):253-7. doi: 10.1007/s00251-015-0829-2. Epub 2015 Feb 27.

PMID:
25721876
31.

Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection.

Watanabe T, Hamada-Tsutsumi S, Yokomaku Y, Imamura J, Sugiura W, Tanaka Y.

Antimicrob Agents Chemother. 2015 Feb;59(2):1292-8. doi: 10.1128/AAC.04459-14. Epub 2014 Dec 15.

32.

Japanese external quality assessment program to standardize HIV-1 drug-resistance testing (JEQS2010 program) using in vitro transcribed RNA as reference material.

Yoshida S, Hattori J, Matsuda M, Okada K, Kazuyama Y, Hashimoto O, Ibe S, Fujisawa S, Chiba H, Tatsumi M, Kato S, Sugiura W.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):318-25. doi: 10.1089/aid.2014.0059. Epub 2014 Dec 3.

33.

Development and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptase.

Gu L, Kawana-Tachikawa A, Shiino T, Nakamura H, Koga M, Kikuchi T, Adachi E, Koibuchi T, Ishida T, Gao GF, Matsushita M, Sugiura W, Iwamoto A, Hosoya N.

PLoS One. 2014 Oct 14;9(10):e109823. doi: 10.1371/journal.pone.0109823. eCollection 2014.

34.

Phylodynamic analysis reveals CRF01_AE dissemination between Japan and neighboring Asian countries and the role of intravenous drug use in transmission.

Shiino T, Hattori J, Yokomaku Y, Iwatani Y, Sugiura W; Japanese Drug Resistance HIV-1 Surveillance Network.

PLoS One. 2014 Jul 15;9(7):e102633. doi: 10.1371/journal.pone.0102633. eCollection 2014.

35.

Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk.

Imahashi M, Izumi T, Watanabe D, Imamura J, Matsuoka K, Ode H, Masaoka T, Sato K, Kaneko N, Ichikawa S, Koyanagi Y, Takaori-Kondo A, Utsumi M, Yokomaku Y, Shirasaka T, Sugiura W, Iwatani Y, Naoe T.

PLoS One. 2014 Mar 25;9(3):e92861. doi: 10.1371/journal.pone.0092861. eCollection 2014.

36.

The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions.

Kudoh A, Takahama S, Sawasaki T, Ode H, Yokoyama M, Okayama A, Ishikawa A, Miyakawa K, Matsunaga S, Kimura H, Sugiura W, Sato H, Hirano H, Ohno S, Yamamoto N, Ryo A.

Retrovirology. 2014 Jan 22;11:9. doi: 10.1186/1742-4690-11-9.

37.

Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.

Nishizawa M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, Sugiura W.

PLoS One. 2013 Dec 16;8(12):e83150. doi: 10.1371/journal.pone.0083150. eCollection 2013.

38.

HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.

Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JA, Ofori SB, Yamaoka S, Ampofo WK, Sugiura W.

PLoS One. 2013 Aug 19;8(8):e71972. doi: 10.1371/journal.pone.0071972. eCollection 2013.

39.

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

Gatanaga H, Murakoshi H, Hachiya A, Hayashida T, Chikata T, Ode H, Tsuchiya K, Sugiura W, Takiguchi M, Oka S.

Clin Infect Dis. 2013 Oct;57(7):1051-5. doi: 10.1093/cid/cit430. Epub 2013 Jun 23.

PMID:
23797286
40.

Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011.

Jahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, Aghasadeghi MR, Mostafavi E, Mohraz M, Jabbari H, Kamali K, Keyvani H, Azadmanesh K, Sugiura W.

PLoS One. 2013 Apr 23;8(4):e61864. doi: 10.1371/journal.pone.0061864. Print 2013.

41.

Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations.

Shibata M, Takahashi M, Yoshino M, Kuwahara T, Nomura T, Yokomaku Y, Sugiura W.

J Med Invest. 2013;60(1-2):35-40.

42.

Seroprevalence of Kaposi's sarcoma-associated herpesvirus among men who have sex with men in Japan.

Katano H, Yokomaku Y, Fukumoto H, Kanno T, Nakayama T, Shingae A, Sugiura W, Ichikawa S, Yasuoka A.

J Med Virol. 2013 Jun;85(6):1046-52. doi: 10.1002/jmv.23558.

PMID:
23588730
43.

TRIM5 genotypes in cynomolgus monkeys primarily influence inter-individual diversity in susceptibility to monkey-tropic human immunodeficiency virus type 1.

Saito A, Nomaguchi M, Kono K, Iwatani Y, Yokoyama M, Yasutomi Y, Sato H, Shioda T, Sugiura W, Matano T, Adachi A, Nakayama EE, Akari H.

J Gen Virol. 2013 Jun;94(Pt 6):1318-24. doi: 10.1099/vir.0.050252-0. Epub 2013 Mar 13.

PMID:
23486671
44.

Association of APOBEC3G genotypes and CD4 decline in Thai and Cambodian HIV-infected children with moderate immune deficiency.

Bunupuradah T, Imahashi M, Iampornsin T, Matsuoka K, Iwatani Y, Puthanakit T, Ananworanich J, Sophonphan J, Mahanontharit A, Naoe T, Vonthanak S, Phanuphak P, Sugiura W; PREDICT Study Team.

AIDS Res Ther. 2012 Nov 24;9(1):34. doi: 10.1186/1742-6405-9-34.

45.

The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α.

Miyamoto T, Nakayama EE, Yokoyama M, Ibe S, Takehara S, Kono K, Yokomaku Y, Pizzato M, Luban J, Sugiura W, Sato H, Shioda T.

PLoS One. 2012;7(10):e47757. doi: 10.1371/journal.pone.0047757. Epub 2012 Oct 19.

46.

The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.

Kitamura S, Ode H, Nakashima M, Imahashi M, Naganawa Y, Kurosawa T, Yokomaku Y, Yamane T, Watanabe N, Suzuki A, Sugiura W, Iwatani Y.

Nat Struct Mol Biol. 2012 Oct;19(10):1005-10. doi: 10.1038/nsmb.2378. Epub 2012 Sep 23.

PMID:
23001005
47.

Molecular epidemiology of HIV type 1 infection in Iran: genomic evidence of CRF35_AD predominance and CRF01_AE infection among individuals associated with injection drug use.

Jahanbakhsh F, Ibe S, Hattori J, Monavari SH, Matsuda M, Maejima M, Iwatani Y, Memarnejadian A, Keyvani H, Azadmanesh K, Sugiura W.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):198-203. doi: 10.1089/AID.2012.0186. Epub 2012 Sep 25.

PMID:
22916738
48.

Molecular dynamics simulation in virus research.

Ode H, Nakashima M, Kitamura S, Sugiura W, Sato H.

Front Microbiol. 2012 Jul 19;3:258. doi: 10.3389/fmicb.2012.00258. eCollection 2012.

49.

[Clinical evaluation of peginterferon α plus ribavirin for patients co-infected with HIV and HCV at Nagoya Medical Center].

Tsuzuki T, Iwase H, Shimada M, Hirashima N, Hibino Y, Ryuge N, Saito M, Tamaki D, Kamiya A, Yokoi M, Yokomaku Y, Fujisaki S, Sugiura W, Goto H.

Nihon Shokakibyo Gakkai Zasshi. 2012 Jul;109(7):1186-96. Japanese.

PMID:
22790623
50.

Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis.

Matsunaga S, Sawasaki T, Ode H, Morishita R, Furukawa A, Sakuma R, Sugiura W, Sato H, Katahira M, Takaori-Kondo A, Yamamoto N, Ryo A.

J Proteomics. 2012 Aug 3;75(15):4863-73. doi: 10.1016/j.jprot.2012.05.047. Epub 2012 Jun 9.

PMID:
22687250

Supplemental Content

Loading ...
Support Center